{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T04:04:23Z","timestamp":1793765063791,"version":"4.6.1"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,10,24]],"date-time":"2017-10-24T00:00:00Z","timestamp":1508803200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2017,10,24]],"date-time":"2017-10-24T00:00:00Z","timestamp":1508803200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["CA134675"],"award-info":[{"award-number":["CA134675"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["CA183031"],"award-info":[{"award-number":["CA183031"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Nucl Med"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1007\/s12149-017-1216-x","type":"journal-article","created":{"date-parts":[[2017,10,24]],"date-time":"2017-10-24T15:43:43Z","timestamp":1508859823000},"page":"69-74","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Low levels of PSMA expression limit the utility of 18F-DCFPyL PET\/CT for imaging urothelial carcinoma"],"prefix":"10.1007","volume":"32","author":[{"given":"Scott P.","family":"Campbell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander S.","family":"Baras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark W.","family":"Ball","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Max","family":"Kates","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noah M.","family":"Hahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trinity J.","family":"Bivalacqua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael H.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin G.","family":"Pomper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamad E.","family":"Allaf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven P.","family":"Rowe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A.","family":"Gorin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,10,24]]},"reference":[{"issue":"4","key":"1216_CR1","doi-asserted-by":"publisher","first-page":"446","DOI":"10.6004\/jnccn.2013.0059","volume":"11","author":"PE Clark","year":"2013","unstructured":"Clark PE, Agarwal N, Biagioli MC, et al. Bladder cancer. J Natl Compr Canc Netw. 2013;11(4):446\u201375.","journal-title":"J Natl Compr Canc Netw"},{"issue":"1","key":"1216_CR2","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1111\/bju.12447","volume":"114","author":"LS Mertens","year":"2014","unstructured":"Mertens LS, Meijer RP, Meinhardt W, et al. Occult lymph node metastases in patients with carcinoma invading bladder muscle: incidence after neoadjuvant chemotherapy and cystectomy vs after cystectomy alone. BJU Int. 2014;114(1):67\u201374.","journal-title":"BJU Int"},{"issue":"5","key":"1216_CR3","doi-asserted-by":"publisher","first-page":"3209","DOI":"10.1007\/s13277-014-2361-7","volume":"36","author":"H Zhang","year":"2015","unstructured":"Zhang H, Xing W, Kang Q, Chen C, Wang L, Lu J. Diagnostic value of [18F] FDG-PET and PET\/CT in urinary bladder cancer: a meta-analysis. Tumour Biol. 2015;36(5):3209\u201314.","journal-title":"Tumour Biol"},{"issue":"9","key":"1216_CR4","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1007\/s00345-016-1772-z","volume":"34","author":"A Soubra","year":"2016","unstructured":"Soubra A, Hayward D, Dahm P. The diagnostic accuracy of 18F-fluorodeoxyglucose positron emission tomography and computed tomography in staging bladder cancer: a single-institution study and a systematic review with meta-analysis. World J Urol. 2016;34(9):1229\u201337.","journal-title":"World J Urol"},{"issue":"3","key":"1216_CR5","doi-asserted-by":"publisher","first-page":"e387-e395","DOI":"10.1016\/j.clgc.2016.08.009","volume":"15","author":"R Pichler","year":"2017","unstructured":"Pichler R, De Zordo T, Fritz J, et al. Pelvic lymph node staging by combined 18F-FDG-PET\/CT imaging in bladder cancer prior to radical cystectomy. Clin Genitourin Cancer. 2017;15(3):e387-e395.","journal-title":"Clin Genitourin Cancer"},{"key":"1216_CR6","doi-asserted-by":"publisher","unstructured":"Vind-Kezunovic S, Bouchelouche K, Ipsen P, H\u00f8yer S, Bell C, Bjerggaard Jensen J. Detection of lymph node metastasis in patients with bladder cancer using maximum standardised uptake value and 18F-fluorodeoxyglucose positron emission tomography\/computed tomography: results from a high-volume centre including long-term follow-up. Eur Urol Focus. 2017. doi:\n                    10.1016\/j.euf.2017.06.005\n                    \n                  .","DOI":"10.1016\/j.euf.2017.06.005"},{"issue":"10","key":"1216_CR7","first-page":"2674","volume":"5","author":"SS Chang","year":"1999","unstructured":"Chang SS, O\u2019Keefe DS, Bacich DJ, Reuter VE, Heston WD, Gaudin PB. Prostate-specific membrane antigen is produced in tumor-associated neovasculature. Clin Cancer Res. 1999;5(10):2674\u201381.","journal-title":"Clin Cancer Res"},{"issue":"13","key":"1216_CR8","first-page":"3192","volume":"59","author":"SS Chang","year":"1999","unstructured":"Chang SS, Reuter VE, Heston WD, Bander NH, Grauer LS, Gaudin PB. Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature. Cancer Res. 1999;59(13):3192\u20138.","journal-title":"Cancer Res"},{"issue":"2","key":"1216_CR9","doi-asserted-by":"publisher","first-page":"38590","DOI":"10.1016\/j.urology.2007.03.025","volume":"70","author":"A Baccala","year":"2007","unstructured":"Baccala A, Sercia L, Li J, Heston W, Zhou M. Expression of prostate-specific membrane antigen in tumor-associated neovasculature of renal neoplasms. Urology. 2007; 70(2):385\u201390.","journal-title":"Urology"},{"issue":"10","key":"1216_CR10","first-page":"4049","volume":"6","author":"JL Gala","year":"2000","unstructured":"Gala JL, Loric S, Guiot Y, et al. Expression of prostate-specific membrane antigen in transitional cell carcinoma of the bladder: prognostic value? Clin Cancer Res. 2000;6(10):4049\u201354.","journal-title":"Clin Cancer Res"},{"issue":"4","key":"1216_CR11","doi-asserted-by":"publisher","first-page":"22635","DOI":"10.1038\/nrurol.2016.26","volume":"13","author":"T Maurer","year":"2016","unstructured":"Maurer T, Eiber M, Schwaiger M, Gschwend JE. Current use of PSMA-PET in prostate cancer management. Nat Rev Urol. 2016;13(4):226\u201335.","journal-title":"Nat Rev Urol"},{"issue":"10","key":"1216_CR12","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1007\/s12149-015-1017-z","volume":"29","author":"SP Rowe","year":"2015","unstructured":"Rowe SP, Gorin MA, Hammers HJ, et al. Imaging of metastatic clear cell renal cell carcinoma with PSMA-targeted 18F-DCFPyL PET\/CT. Ann Nucl Med. 2015;29(10):877\u201382.","journal-title":"Ann Nucl Med"},{"issue":"1","key":"1216_CR13","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1097\/RLU.0000000000000995","volume":"41","author":"SP Rowe","year":"2016","unstructured":"Rowe SP, Gorin MA, Hammers HJ, Pomper MG, Allaf ME, Javadi MS. Detection of 18F-FDG PET\/CT occult lesions with 18F-DCFPyL PET\/CT in a patient with metastatic renal cell carcinoma. Clin Nucl Med. 2016;41(1):83\u20135.","journal-title":"Clin Nucl Med"},{"issue":"1","key":"1216_CR14","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s13550-016-0231-6","volume":"6","author":"H Rhee","year":"2016","unstructured":"Rhee H, Blazak J, Tham CM, et al. Pilot study: use of gallium-68 PSMA PET for detection of metastatic lesions in patients with renal tumour. EJNMMI Res. 2016;6(1):76.","journal-title":"EJNMMI Res"},{"issue":"1","key":"1216_CR15","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.eururo.2016.06.019","volume":"71","author":"MA Gorin","year":"2017","unstructured":"Gorin MA, Rowe SP, Hooper JE, et al. PSMA-Targeted 18F-DCFPyL PET\/CT imaging of clear cell renal cell carcinoma: results from a rapid autopsy. Eur Urol. 2017;71(1):145\u20136.","journal-title":"Eur Urol"},{"issue":"1","key":"1216_CR16","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1007\/s00259-016-3360-2","volume":"44","author":"LM Sawicki","year":"2017","unstructured":"Sawicki LM, Buchbender C, Boos J, et al. Diagnostic potential of PET\/CT using a 68Ga-labelled prostate-specific membrane antigen ligand in whole-body staging of renal cell carcinoma: initial experience. Eur J Nucl Med Mol Imaging. 2017;44(1):102\u20137.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"6","key":"1216_CR17","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1097\/RLU.0000000000001646","volume":"42","author":"A Sasikumar","year":"2017","unstructured":"Sasikumar A, Joy A, Pillai MRA, Alex TM, Narayanan G. 68Ga-PSMA PET\/CT in osteosarcoma in fibrous dysplasia. Clin Nucl Med. 2017;42(6):446\u20137.","journal-title":"Clin Nucl Med"},{"issue":"1","key":"1216_CR18","doi-asserted-by":"publisher","first-page":"e41-e48","DOI":"10.1097\/RLU.0000000000001451","volume":"42","author":"A Sasikumar","year":"2017","unstructured":"Sasikumar A, Joy A, Pillai MR, et al. Diagnostic value of 68Ga-PSMA-11 PET\/CT imaging of brain tumors-preliminary analysis. Clin Nucl Med. 2017;42(1):e41-e48.","journal-title":"Clin Nucl Med"},{"issue":"4","key":"1216_CR19","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1007\/s00259-016-3563-6","volume":"44","author":"M Sathekge","year":"2017","unstructured":"Sathekge M, Lengana T, Modiselle M, et al. 68Ga-PSMA-HBED-CC PET imaging in breast carcinoma patients. Eur J Nucl Med Mol Imaging. 2017;44(4):689\u201394.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"10","key":"1216_CR20","doi-asserted-by":"publisher","first-page":"e447-e448","DOI":"10.1097\/RLU.0000000000001774","volume":"42","author":"A Sasikumar","year":"2017","unstructured":"Sasikumar A, Joy A, Pillai M, Bindu S, Sudin SR. Ga-PSMA uptake in an incidentally detected gastrointestinal stromal tumor in a case of suspected carcinoma prostate. Clin Nucl Med. 2017;42(10):e447-e448.","journal-title":"Clin Nucl Med"},{"issue":"4","key":"1216_CR21","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1007\/s00259-015-3297-x","volume":"43","author":"A Sasikumar","year":"2016","unstructured":"Sasikumar A, Joy A, Nanabala R, Pillai MR, Thomas B, Vikraman KR. 68Ga-PSMA PET\/CT imaging in primary hepatocellular carcinoma. Eur J Nucl Med Mol Imaging. 2016;43(4):795\u20136.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"10","key":"1216_CR22","doi-asserted-by":"publisher","first-page":"1622","DOI":"10.1007\/s00259-015-3065-y","volume":"42","author":"FA Verburg","year":"2015","unstructured":"Verburg FA, Krohn T, Heinzel A, Mottaghy FM, Behrendt FF. First evidence of PSMA expression in differentiated thyroid cancer using [68Ga]PSMA-HBED-CC PET\/CT. Eur J Nucl Med Mol Imaging. 2015;42(10):1622\u20133.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1216_CR23","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s13550-015-0104-4","volume":"5","author":"N Pandit-Taskar","year":"2015","unstructured":"Pandit-Taskar N, O\u2019Donoghue JA, Divgi CR, et al. Indium 111-labeled J591 anti-PSMA antibody for vascular targeted imaging in progressive solid tumors. EJNMMI Res. 2015;5:28.","journal-title":"EJNMMI Res"},{"issue":"5","key":"1216_CR24","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1200\/JCO.2006.07.8097","volume":"25","author":"MI Milowsky","year":"2007","unstructured":"Milowsky MI, Nanus DM, Kostakoglu L, et al. Vascular targeted therapy with anti-prostate-specific membrane antigen monoclonal antibody J591 in advanced solid tumors. J Clin Oncol. 2007;25(5):540\u20137.","journal-title":"J Clin Oncol"},{"issue":"3","key":"1216_CR25","doi-asserted-by":"publisher","first-page":"222","DOI":"10.4103\/0972-3919.183615","volume":"31","author":"M Gupta","year":"2016","unstructured":"Gupta M, Choudhury PS, Gupta G, Gandhi J. Metastasis in urothelial carcinoma mimicking prostate cancer metastasis in Ga-68 prostate-specific membrane antigen positron emission tomography-computed tomography in a case of synchronous malignancy. Indian J Nucl Med. 2016;31(3):222\u20134.","journal-title":"Indian J Nucl Med"},{"issue":"4","key":"1216_CR26","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1007\/s11307-015-0850-8","volume":"17","author":"Z Szabo","year":"2015","unstructured":"Szabo Z, Mena E, Rowe SP, et al. Initial evaluation of [18F]DCFPyL for prostate-specific membrane antigen (PSMA)-targeted PET imaging of prostate cancer. Mol Imaging Biol. 2015;17(4):565 \u2013 74.","journal-title":"Mol Imaging Biol"},{"issue":"suppl 3","key":"1216_CR27","first-page":"90S96S","volume":"57","author":"SP Rowe","year":"2016","unstructured":"Rowe SP, Drzezga A, Neumaier B, et al. Prostate-specific membrane antigen-targeted radiohalogenated PET and therapeutic agents for prostate cancer. J Nucl Med. 2016;57(suppl 3):90S\u201396S.","journal-title":"J Nucl Med"},{"issue":"2","key":"1216_CR28","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.cpet.2016.12.006","volume":"12","author":"SP Rowe","year":"2017","unstructured":"Rowe SP, Gorin MA, Salas Fragomeni RA, Drzezga A, Pomper MG. Clinical experience with 18F-labeled small molecule inhibitors of prostate-specific membrane antigen. PET Clin. 2017;12(2):235\u201341.","journal-title":"PET Clin"},{"issue":"4","key":"1216_CR29","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1007\/s11307-015-0866-0","volume":"17","author":"M Dietlein","year":"2015","unstructured":"Dietlein M, Kobe C, Kuhnert G, et al. Comparison of [18F]DCFPyL and [68Ga]PSMA-HBED-CC for PSMA-PET imaging in patients with relapsed prostate cancer. Mol Imaging Biol. 2015;17(4):575 \u2013 84.","journal-title":"Mol Imaging Biol"},{"issue":"6","key":"1216_CR30","doi-asserted-by":"publisher","first-page":"947","DOI":"10.2967\/jnumed.116.185538","volume":"58","author":"F Dietlein","year":"2017","unstructured":"Dietlein F, Kobe C, Neubauer S, et al. PSA-stratified performance of 18F- and 68Ga-PSMA PET in patients with biochemical recurrence of prostate cancer. J Nucl Med. 2017;58(6):947\u201352.","journal-title":"J Nucl Med"},{"key":"1216_CR31","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1186\/1471-2105-12-323","volume":"12","author":"B Li","year":"2011","unstructured":"Li B, Dewey CN. RSEM: accurate transcript quantification from RNA-seq data with or without a reference genome. BMC Bioinf. 2011;12:323.","journal-title":"BMC Bioinf"},{"issue":"18","key":"1216_CR32","doi-asserted-by":"publisher","first-page":"e178","DOI":"10.1093\/nar\/gkq622","volume":"38","author":"K Wang","year":"2010","unstructured":"Wang K, Singh D, Zeng Z, et al. MapSplice: accurate mapping of RNA-seq reads for splice junction discovery. Nucleic Acids Res. 2010;38(18):e178.","journal-title":"Nucleic Acids Res"}],"container-title":["Annals of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12149-017-1216-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12149-017-1216-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12149-017-1216-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,14]],"date-time":"2020-05-14T09:49:07Z","timestamp":1589449747000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12149-017-1216-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10,24]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,1]]}},"alternative-id":["1216"],"URL":"https:\/\/doi.org\/10.1007\/s12149-017-1216-x","relation":{},"ISSN":["0914-7187","1864-6433"],"issn-type":[{"value":"0914-7187","type":"print"},{"value":"1864-6433","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,10,24]]},"assertion":[{"value":"18 October 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 October 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 October 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"M.G.P. is a coinventor on a U.S. Patent covering <sup>18<\/sup>F-DCFPyL, and as such is entitled to a portion of any licensing fees and royalties generated by this technology. This arrangement has been reviewed and approved by the Johns Hopkins University in accordance with its conflict-of-interest policies. M.A.G. has served as a consultant to Progenics Pharmaceuticals, the licensee of <sup>18<\/sup>F-DCFPyL. M.A.G., M.G.P., and S.P.R. have received research support from Progenics Pharmaceuticals.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}